Atanasio
Pandiella Alonso
Hospital Universitario de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (37)
2023
-
An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer
Journal of experimental & clinical cancer research : CR, Vol. 42, Núm. 1, pp. 200
-
Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications
Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257
2022
-
ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology
Cancers, Vol. 14, Núm. 14
-
Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
2021
-
Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma
Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1
-
Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer
npj Precision Oncology, Vol. 5, Núm. 1
2019
-
MEK5 promotes lung adenocarcinoma
The European respiratory journal
2015
-
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
Leukemia, Vol. 29, Núm. 3, pp. 705-714
2014
-
Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer
Oncogene, Vol. 33, Núm. 2, pp. 148-156
-
Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 Inhibition as an antimyeloma strategy
Molecular Cancer Therapeutics, Vol. 13, Núm. 2, pp. 504-516
-
NADPH oxidases as therapeutic targets in chronic myelogenous leukemia
Clinical Cancer Research, Vol. 20, Núm. 15, pp. 4014-4025
-
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease
Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305
2013
-
Potent antimyeloma activity of a novel ERK5/CDK inhibitor
Clinical Cancer Research, Vol. 19, Núm. 10, pp. 2677-2687
-
RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications
Investigational New Drugs, Vol. 31, Núm. 1, pp. 200-205
-
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
Leukemia, Vol. 27, Núm. 2, pp. 430-440
2012
-
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype
Haematologica, Vol. 97, Núm. 7, pp. 1110-1114
-
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients
Leukemia, Vol. 26, Núm. 8, pp. 1862-1869
-
Dasatinib as a bone-modifying agent: Anabolic and anti-resorptive effects
PLoS ONE, Vol. 7, Núm. 4
2011
-
Deficient spindle assembly checkpoint in multiple myeloma
PLoS ONE, Vol. 6, Núm. 11
-
Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response
Haematologica, Vol. 96, Núm. 5, pp. 687-695